Compare Conagra Brands Inc (CAG) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Conagra Brands Inc vs Viatris Inc — how do they compare? Conagra Brands Inc trades at $15.36 (market cap $7.18B), while Viatris Inc trades at $16.1 (market cap $18.49B). The key difference: Viatris Inc is far larger — about 2.6× Conagra Brands Inc's market cap, and Conagra Brands Inc pays the higher dividend (8.19%). Which is the better fit depends on your goals.
| CAG | VTRS | |
|---|---|---|
Market Cap | $7.18B | $18.49B |
Sector | Consumer Staples | Health |
52-Week High | $20.02 | $17.86 |
52-Week Low | $12.58 | $9.49 |
Enterprise Value | $14.23B | $30.61B |
Dividend Yield | 8.19% | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Conagra Brands (CAG) trades at $15.385, up 2.94% today, with a bullish technical signal and mixed earnings history. The stock shows attractive valuation with a P/E of 10.06 and P/S of 0.64, but faces challenges including a net income margin of -16.99% for 2026 and a recent 50% dividend cut. Recent news highlights leadership changes and strategic shifts under new CEO John Brase to streamline operations and address margin pressures amid inflationary headwinds.
The outlook is cautious; while low valuation provides downside support, persistent sales declines and margin compression pose risks. Analyst consensus is mixed with a $13.67 price target below current levels, indicating skepticism about near-term recovery. Investors should weigh the potential for a turnaround against ongoing operational and macroeconomic challenges.
Viatris (VTRS) trades at $16.04, down 1.47% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.69 exceeding expectations by 14.8%. Recent FDA approval for Gwyn Lo contraceptive patch and divestiture of Tyrvaya nasal spray demonstrate strategic portfolio optimization. Revenue trends show stabilization after declining from $16.3B in 2022 to $14.3B in 2025, with 2026 projections at $14.7B.
While Viatris shows operational strength with consistent cash flow generation and debt reduction, the company faces profitability challenges with negative net income margins and elevated P/E ratio of 236.2. Analyst sentiment is cautiously optimistic with 30.8% buy ratings, though the majority (61.5%) recommend hold. Key risks include ongoing margin pressure, generic drug pricing headwinds, and execution of strategic initiatives amid competitive pharmaceutical landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
